Pulling SEC filings + quote and writing the call…
EDIT
Editas Medicine, Inc.
Next earnings Aug 10, 2026 · consensus $-0.27 EPS, $2.86M rev
Last earnings +1.3% on 2026-05-05
$2.69
▲ +5.49%$2.69▲ +24.54%
over 1Y
L $1.67EODHDH $4.15
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+5.5%
1W+10.2%
1M+9.3%
3M+14.5%
YTD+31.2%
1Y+24.5%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 19 analysts
Buy
Revenue grew 25.4% YoY; but unprofitable (net margin -395.0%).
Editas Medicine, Inc. shows $40.5M in FY2025 revenue (+25.4% YoY), a -395.0% net margin, and -586.6% ROE.
Sources: SEC EDGAR (CIK 0001650664, latest 10-Q filed 2026-05-05) · EODHD · as of 6/22/2026, 1:41:05 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.